SAN

81.9

+0.05%↑

MRK1

120.45

+0.67%↑

SHL.DE

44.51

-0.65%↓

ARGX

717

-0.83%↓

FRE

48.76

+0.52%↑

SAN

81.9

+0.05%↑

MRK1

120.45

+0.67%↑

SHL.DE

44.51

-0.65%↓

ARGX

717

-0.83%↓

FRE

48.76

+0.52%↑

SAN

81.9

+0.05%↑

MRK1

120.45

+0.67%↑

SHL.DE

44.51

-0.65%↓

ARGX

717

-0.83%↓

FRE

48.76

+0.52%↑

SAN

81.9

+0.05%↑

MRK1

120.45

+0.67%↑

SHL.DE

44.51

-0.65%↓

ARGX

717

-0.83%↓

FRE

48.76

+0.52%↑

SAN

81.9

+0.05%↑

MRK1

120.45

+0.67%↑

SHL.DE

44.51

-0.65%↓

ARGX

717

-0.83%↓

FRE

48.76

+0.52%↑

Home・Aandelen Lijst・Pharming Group NV

P
Pharming Group NV

Open

1.431 -1.38

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.418

Max

1.457

Belangrijke statistieken
By Trading Economics
Inkomsten	2.9M 7.5M
Verkoop	4.1M 97M
EPS	0.009
Winstmarge	7.758
Werknemers	404

Marktinformatie
By TradingEconomics
Marktkapitalisatie	24M 1B
Vorige openingsprijs	2.81
Vorige sluitingsprijs	1.431

Pharming Group NV Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

23 dec 2025, 15:21 UTC

Winsten

Correction to Home Depot Outlook Headline on Dec. 9

23 dec 2025, 23:54 UTC

Marktinformatie

Gold Climbs Above $4,500/oz for First Time Amid Rising Geopolitical Tensions -- Market Talk

23 dec 2025, 23:40 UTC

Marktinformatie

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

23 dec 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

23 dec 2025, 21:21 UTC

Acquisities, Fusies, Overnames

St Barbara to Use Deposit Toward A$370 Million Subscription to Buy 50% of Simberi Unit

23 dec 2025, 21:20 UTC

Acquisities, Fusies, Overnames

St Barbara to Hold Deposit in Escrow

23 dec 2025, 21:20 UTC

Acquisities, Fusies, Overnames

St Barbara: Deposit Represents Progress on Lingbao's Strategic Investment in Simberi Mine

23 dec 2025, 21:19 UTC

Acquisities, Fusies, Overnames

St Barbara Receives A$32 Million Deposit From Lingbao Gold

23 dec 2025, 21:13 UTC

Acquisities, Fusies, Overnames

ServiceNow Bets on Cybersecurity to Boost Growth -- Analysis

23 dec 2025, 20:16 UTC

Marktinformatie

Oil Futures Settle Higher on Geopolitical Tensions -- Market Talk

23 dec 2025, 20:14 UTC

Marktinformatie

U.S. Natural Gas Soars on Colder Weather Outlook -- Market Talk

23 dec 2025, 19:13 UTC

Winsten

Acquisities, Fusies, Overnames

Mergers and Acquisitions Soared This Year. 2026 Could Be Even Bigger. -- Barrons.com

23 dec 2025, 18:58 UTC

Marktinformatie

Gold Has Another Record-Setting Day -- Market Talk

23 dec 2025, 18:32 UTC

Marktinformatie

U.S. Oil Rig Count Rises By 3 to 409 -- Market Talk

23 dec 2025, 17:20 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Tech, Media & Telecom Roundup: Market Talk

23 dec 2025, 17:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

23 dec 2025, 17:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

23 dec 2025, 17:09 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Armis Seen as Good Fit for ServiceNow in $7.8B Deal -- Market Talk

23 dec 2025, 16:21 UTC

Marktinformatie

Monthly Canadian GDP Points to Flat Activity So Far for 4Q -- Market Talk

23 dec 2025, 16:16 UTC

Marktinformatie

Recent 'Disorderly' Yen Falls Could Justify Intervention -- Market Talk

23 dec 2025, 16:15 UTC

Marktinformatie

Precious Metals Pare Gains -- Market Talk

23 dec 2025, 16:03 UTC

Acquisities, Fusies, Overnames

Erste Group Bank: Closing Expected Around Mid-January

23 dec 2025, 16:03 UTC

Acquisities, Fusies, Overnames

Erste Group Bank Also Obtained Regulatory Approvals for 50% Stake in Santander Towarzystwo Funduszy Inwestycyjnych

23 dec 2025, 16:02 UTC

Acquisities, Fusies, Overnames

Erste Group Bank Obtained Regulatory Approvals by Polish Regulator KNF for Acquisition of Roughly 49% Controlling Stake in Santander Bank Polska

23 dec 2025, 16:01 UTC

Acquisities, Fusies, Overnames

Erste Group Bank Receives Green Light for Acquisition in Poland

23 dec 2025, 15:42 UTC

Acquisities, Fusies, Overnames

Telefonica: Agreement is For Sale of Telefonica Tech Business in Colombia, Mexico, Chile

23 dec 2025, 15:42 UTC

Acquisities, Fusies, Overnames

Telefonica Doesn't Set Out Financial Details of Divestment

23 dec 2025, 15:41 UTC

Acquisities, Fusies, Overnames

Telefonica: Deal Will Allow Focus on Core Markets

23 dec 2025, 15:40 UTC

Acquisities, Fusies, Overnames

Telefonica To Sell Telefonica Tech South American Business to Hiberus

23 dec 2025, 15:19 UTC

Marktinformatie

Fixed-Income Traders Misread Underlying Strength of Canada Economy -- Market Talk

Peer Vergelijking

Prijswijziging

Pharming Group NV Prognose

Beoordelingsconsensus

By TipRanks

0 ratings

Buy

Hold

Sell

Gebaseerd op 0 analisten die aandelenratings hebben gegeven aan Pharming Group NV - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.